Comparative Pharmacology
Head-to-head clinical analysis: SPRX 105 versus ZURAGARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SPRX 105 versus ZURAGARD.
SPRX-105 vs ZURAGARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SPRX-105 is a dual dopamine D2 and serotonin 5-HT1A receptor partial agonist, functioning as a postsynaptic antagonist and presynaptic agonist at D2 receptors, and as a partial agonist at 5-HT1A receptors, modulating neurotransmitter release.
ZURAGARD (zagociguat) is a soluble guanylate cyclase (sGC) stimulator that enhances the sensitivity of sGC to nitric oxide (NO) and directly stimulates sGC independently of NO, leading to increased cyclic guanosine monophosphate (cGMP) production. This results in vasodilation and improved hemodynamics.
SPRX-105 is administered orally at a dose of 50 mg once daily.
16 mg/kg intravenously every 12 hours for 2 days, followed by 8 mg/kg intravenously every 12 hours for 3 days.
None Documented
None Documented
12-15 hours in healthy adults; extended to 24-30 hours in renal impairment.
Terminal elimination half-life is approximately 14-18 hours in healthy adults, allowing once-daily dosing; may be prolonged in renal impairment (up to 40 hours in severe impairment).
Primarily renal (70-80% unchanged) with 15-20% biliary/fecal elimination.
Primarily renal excretion (60-70% as unchanged drug); biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Unknown
Unknown